key: cord-0281223-hft1i4r8
authors: Davis, Alicia; Morris, Kevin V.; Shevchenko, Galina
title: Hypoxia-directed tumor targeting of CRISPR/Cas9 and HSV-TK suicide gene therapy using lipid nanoparticles
date: 2021-09-30
journal: bioRxiv
DOI: 10.1101/2021.09.30.462477
sha: 0107fc37a08d978bd2bf4a7005ab02721e735cbc
doc_id: 281223
cord_uid: hft1i4r8

Hypoxia is a characteristic feature of solid tumors that contributes to tumor aggressiveness and is associated with resistance to cancer therapy. The hypoxia inducible factor-1 (HIF-1) transcription factor complex mediates hypoxia-specific gene expression by binding to hypoxia responsive element (HRE) sequences within the promoter of target genes. HRE driven expression of therapeutic cargo has been widely explored as a strategy to achieve cancer-specific gene expression. By utilizing this system, we achieve hypoxia-specific expression of two therapeutically relevant cargo elements: the Herpes Simplex Virus thymidine kinase (HSV-tk) suicide gene and the CRISPR/Cas9 nuclease. Using an expression vector containing five copies of the HRE derived from the vascular endothelial growth factor gene, we are able to show high transgene expression in cells in a hypoxic environment, similar to levels achieved using the CMV and CBh promoters. Furthermore, we are able to deliver our therapeutic cargo to tumor cells with high efficiency using plasmid packaged lipid nanoparticles (LNPs) to achieve specific killing of tumor cells in hypoxic conditions, while maintaining tight regulation with no significant changes to cell viability in normoxia.

2 Abstract: Hypoxia is a characteristic feature of solid tumors that contributes to tumor 22 aggressiveness and is associated with resistance to cancer therapy. The hypoxia inducible factor-23 1 (HIF-1) transcription factor complex mediates hypoxia-specific gene expression by binding to 24 hypoxia responsive element (HRE) sequences within the promoter of target genes. HRE driven 25 expression of therapeutic cargo has been widely explored as a strategy to achieve cancer-specific 26 gene expression. By utilizing this system, we achieve hypoxia-specific expression of two 27 therapeutically relevant cargo elements: the Herpes Simplex Virus thymidine kinase (HSV-tk) 28 suicide gene and the CRISPR/Cas9 nuclease. Using an expression vector containing five copies 29 of the HRE derived from the vascular endothelial growth factor gene, we are able to show high 30 transgene expression in cells in a hypoxic environment, similar to levels achieved using the CMV 31 and CBh promoters. Furthermore, we are able to deliver our therapeutic cargo to tumor cells with 32 high efficiency using plasmid packaged lipid nanoparticles (LNPs) to achieve specific killing of 33

Introduction 36

Over recent years, many advances have been made in cancer therapy, including the 37 development of targeted inhibitors and immunotherapies with greatly reduced adverse effects. 38

Despite this, the current 5-year survival rate among all cancers is only 68%, dropping to under 39 10% for certain cancer types, including pancreatic cancer and glioblastoma (1) . The resistance of 40 these high-risk cancers to current therapies begets a need to develop novel treatment modalities 41 to improve patient survival and quality of life. Several unique cancer treatment strategies have 42 emerged by repurposing proteins found in viruses and bacteria to promote cell death, including 43 the Human Simplex Virus thymidine kinase (HSV-tk) suicide gene and the CRISPR/Cas9 44 nuclease. Although both of these proteins have shown promise as a treatment option for various 45 cancers, there is a growing need to direct tumor-specific expression of these proteins in order to 46 minimize the risk of off-target toxicity and, in the case of Cas9, off-target mutations. 47

The hypoxic microenvironment offers a unique opportunity to target these exogenous 48 proteins to regions of the tumor where the most aggressive and treatment resistant cancer cells 49 often reside. Solid tumors account for approximately 90% of all human malignancies (2). As a 50 result of vascular abnormalities that lead to low intratumoral blood flow, up to 50-60% of locally 51 advanced solid tumors develop areas of low O2 (<10 mmHg) partial pressure compared to their 52 surrounding tissues (3-5). This hypoxic state has been associated with increased tumor 53 aggressiveness and resistance to current therapies (6). Of all the proteins induced by hypoxic 54 All data are presented as mean ± S.D. and are representative of a minimum of two independent 243 experiments. Statistical analysis was performed using Prism v.9.1.2 (GraphPad). Comparisons of 244 three or more groups were analyzed using one-way or two-way ANOVA tests, when appropriate. 245

One-way ANOVA tests were corrected for multiple comparisons using the Dunnett correction 246 method, while two-way ANOVA tests were corrected using the Tukey method. P-value < 0.05 was 247 considered statistically significant. 248 249

Development and characterization of a hypoxia regulated protein expression system 251

In order to determine the best combination of regulatory elements for hypoxia-specific 252 gene expression, we conducted a luciferase screen in HeLa cells in the presence or absence of 253 the hypoxia mimetic BAY 85-3934 ( Figure S1A ). BAY 85-3934 is a potent small-molecule inhibitor 254 of HIF prolyl hydroxylases that stabilizes HIF1⍺ from proteasomal degradation (26). We confirmed 255 its ability to stabilize HIF1⍺ using a HRE eGFP reporter ( Figure 1A ) and were able to see induction 256 of HIF1⍺ protein by western blot to levels similar to those achieved in true hypoxia ( Figure 1B Hela and U251 cells ( Figure 2B and Figure S2A ). In the absence of the hypoxia mimetic or hypoxia 294 treatment there is no detectable protein expression of HSV-tk from the HRE constructs. 295

Interestingly, HRE-HSV-tk WT protein expression under hypoxia is at nearly the same level as 296 the CMV counterpart. Cells transfected with CMV HSV-tk WT or mutant 30 display reduced 297 viability as expected when treated with GCV ( Figure 2C and Figure Figure 2D ). Collectively, these data demonstrate that HRE driven expression of 304 HSV-tk WT or mutant 30 is tightly regulated and significantly reduces cell viability only during 305 hypoxic conditions. 306 307 Hypoxia-specific expression of CRISPR/Cas9 308 The Cas9 protein is a repurposed prokaryotic RNA-guided dsDNA nuclease used for 309 mammalian gene editing that can be programmed to cut any genomic locus. CRISPR-Cas9 offers 310 a unique opportunity to treat cancer by permanently disrupting genes essential for tumor cell 311 survival. However, there is currently no reliable way to specifically deliver and express the 312 CRISPR-Cas9 nuclease in cancer cells. To overcome this limitation, many efforts have focused 313 on targeting unique sequence variants that are found only in cancer cells, such as viral and fusion 314 oncogenes (37-40), minimizing the risk of any potential toxicity in normal tissue. Nevertheless, in 315 addition to the largely limited number of targets that can be pursued with this approach, there is 316 also a growing concern about the risks of off-target mutations that can arise with unchecked 317 expression of the Cas9 throughout the body (41-43). Based on these concerns, we set out to 318 14 evaluate the potential of an HRE-directed CRISPR/Cas9 to specifically induce cancer cell death 319 in hypoxia. 320

To determine the best gRNA targets, we screened gRNAs targeting polo-like kinase 1 321 (PLK1) and the consensus sequence of AluY elements for their ability to suppress cancer cell 322 growth. Polo-like kinase 1 (PLK1) has been extensively evaluated as both an siRNA and Cas9 323 target to induce apoptosis in a broad range of cancer cells (44,45). Consistent with previous work, 324 all gRNAs targeting PLK1 suppressed cell viability, with gRNA-3 being used in all subsequent 325 experiments as it appeared to be the most potent in multiple cell lines (Figures 3A and S3A) . A 326 gRNA against the consensus AluY sequence was further included as it has the potential to induce 327 thousands of dsDNA breaks throughout the genome, leading to a significant reduction in cell 328 viability ( Figures 3A and S3A) . 329

To determine the feasibility and efficacy of a hypoxia-regulated Cas9 expression system, 330

we transfected cells with the Cas9 nuclease expressed from either the CBh or the 5HRE promoter 331 ( Figure 3B ). We observed HRE-specific expression of the Cas9 nuclease in cells cultured with 332 the hypoxia mimetic BAY 85-3934 or in hypoxia, with almost undetectable levels of expression in 333 control conditions ( Figure 3C and S3B ). We saw a significant reduction in cell viability in cells 334 transfected with the AluY and PLK1 gRNAs when the Cas9 nuclease was expressed from the 335 CBh promoter in all conditions ( Figure 3D and S3C ). However, a significant reduction in cell 336 viability was only observed when cells were treated in hypoxic conditions when these gRNAs 337 were expressed in the presence of the HRE-driven Cas9 ( Figure 3D and S3C) . For cells treated 338 with the AluY gRNAs, we observed an increase in DNA damage using the HRE driven Cas9 339 nuclease only in hypoxic conditions, while there was evidence of DNA damage in both hypoxic 340 and normoxic conditions using the CBh driven Cas9 ( Figure 3E ). Next, we wanted to confirm that 341

Cas9 cleavage was only observed in hypoxic conditions when the expression of the nuclease is 342 driven from the HRE promoter. To this end, we utilized a reporter cell line containing an eGFP 343 firefly luciferase fusion protein. Cas9 cleavage with our eGFP gRNA results in the disruption of 344 the fusion protein in these cells, giving us an opportunity to use the expression of eGFP and 345 luciferase as an indicator of Cas9 activity. We observed a specific reduction in luciferase signal 346 in a hypoxia regulated fashion for cells transfected with the HRE regulated Cas9 construct (Figure  347 S3D). However, as this was not a direct measure of Cas9 cleavage activity, we performed a T7 348

Endonuclease I cleavage assay in order to directly survey genomic editing at the PLK1 locus. We 349 were able to show hypoxia regulated Cas9 mediated editing at the PLK1 locus, with minimal 350 cleavage at this locus in normoxic conditions ( Figure 3F and S3E) . Overall, we demonstrate a 351 HRE promoter driven Cas9 system that is capable of specifically reducing the viability of hypoxic 352 cancer cells. 353 354 Delivery using LNPs 355

As our method for achieving hypoxia-specific expression for HSV-tk and Cas9 requires 356 transcriptional activation at the promoter level, we needed a vehicle that could facilitate delivery 357 of a DNA-based system in order to achieve regulated expression of these genes. While AAV has 358 been widely used as a vector for gene therapy to deliver DNA sequences to target cells, the large 359 size of the spCas9 nuclease together with its gRNA (~5kb) makes it largely incompatible with an 360 AAV-based delivery vehicle due to the ~4.7kb packaging capacity of AAVs. In light of this, we 361 decided to deliver these transgenes using plasmid packaged lipid nanoparticles (LNPs). GFP plasmid. In order to test the feasibility of delivering a Cas9 plasmid, we encapsulated a 9.3kb 371 Cas9-T2A-eGFP plasmid into LNPs using a nitrogen to phosphate (N:P) ratio of 6. Flow cytometry 372 analysis of eGFP expression 48 hours after LNP treatment demonstrates efficient delivery of the 373 plasmid into cells ( Figure S4A ). Furthermore, these LNPs are well tolerated as all cell lines tested 374 remain greater than 90% viable 48 hours after treatment ( Figure S4B) . LNPs displayed a significant reduction in cell viability in HRE HSV-tk constructs cultured in GCV 390 with hypoxia mimetic or true hypoxia ( Figures 4D and S4E-F) . In contrast, little to no change in 391 viability was observed in HeLa cells receiving HRE driven HSV-tk LNPs in the presence of GCV 392 and DMSO. Likewise, we were able to observe a significant reduction in cell viability in a hypoxia 393 regulated manner for cells treated with HRE-Cas9 packaged LNPs ( Figure 4E and S4G ). Cas9 394 mediated cleavage was, once again, shown to occur in a hypoxia specific fashion at the PLK1 395 locus for cells treated with Cas9 expressed from the HRE promoter ( Figures 4F and S4H) hypoxic cells are known to be more resistant to radio-and chemotherapy (3,6). In addition to this, 405 selective killing of HIF1⍺-expressing tumor cells has been shown to reduce metastatic 406 progression and improve survival (49), suggesting that targeting these cells is a viable therapeutic 407 strategy. In this study, we developed an LNP-based platform to deliver therapeutically relevant 408 cargo to hypoxic tumor cells. We focused our efforts on delivery of two different anti-cancer 409 therapeutic systems: HSV-tk and the spCas9 nuclease. Using 5HRE driven expression, we were 410 able to show LNP-delivered robust and specific expression of these proteins in hypoxic conditions, 411 with minimal off-target activity in normoxic conditions in multiple cancer cell lines. Notably, we 412 were able to reach similar levels of activity when delivering our DNA constructs through LNPs 413 formulated within our lab when compared to commercially available transfection reagents. 414

Our proof-of-concept work demonstrates an effective delivery of a hypoxia responsive 415 HSV-tk and CRISPR/Cas9 system using nanoparticles; however, further optimization to include 416 additional levels of regulation should be explored. Although we observe a strong induction of gene 417 expression using the 5HRE promoter during hypoxic culture conditions, a small amount of 418 baseline expression persists in control cells. One method to help reduce baseline expression from 419 the 5HRE promoter is to optimize the incorporation of the HIF1⍺ ODD. Installing two layers of 420 regulation with the 5HRE and ODD would greatly limit any residual expression in normoxia which 421 has been demonstrated in CAR-T cells (9). To further tailor the 5HRE system for expression in 422 

2. Hematopoietic Cancers. Primer to the Immune Response

Hypoxia in cancer: significance and impact on clinical outcome. Cancer 541 Metastasis Rev

Hypoxia and its 543 therapeutic possibilities in paediatric cancers

Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular 546

The clinical significance of hypoxia in human cancers

Regulation of hypoxia-inducible factor 1alpha is mediated by an 550

O2-dependent degradation domain via the ubiquitin-proteasome pathway

Non-Canonical Mechanisms Regulating Hypoxia-553

Inducible Factor 1 Alpha in Cancer. Front Oncol [Internet]. Frontiers

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors

Antitumor Effect of TAT-Oxygen-dependent Degradation-559

Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells

Adenovirus-mediated 562 hypoxia-targeted gene therapy using HSV thymidine kinase and bacterial nitroreductase prodrug-563 activating genes in vitro and in vivo

Development of a hypoxia-responsive vector for tumor-specific 565 gene therapy

Progress and problems with the use of suicide genes for targeted cancer 567 therapy

Adenovirus-mediated 569 gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with 570 operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial

A multifunctional AAV-573 CRISPR-Cas9 and its host response

Delivery approaches for CRISPR/Cas9 575 therapeutics in vivo: advances and challenges

Human Immune Responses to Adeno-Associated Virus

The Promise and Challenge of In Vivo Delivery for Genome Therapeutics

Engineering precision 581 nanoparticles for drug delivery

Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

Lipid nanoparticles for targeted siRNA delivery -going 586 from bench to bedside

Systemic nanoparticle delivery of CRISPR-Cas9 588 ribonucleoproteins for effective tissue specific genome editing

Design of lipid 591 nanoparticles for in vitro and in vivo delivery of plasmid DNA

Lipid Nanoparticles Enabling Gene Therapies: From 593 Concepts to Clinical Utility

High-595 throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell 596 gene editing

Mimicking hypoxia to treat 598 anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without 599 hypertensive effects

Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense 602

Mobilize Chimeric Antigen Receptors against HIV

Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

Green fluorescent protein is a suitable reporter of tumor hypoxia 609 despite an oxygen requirement for chromophore formation

A pharmacodynamic model of 611 ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat 612 cytomegalovirus infection

Ganciclovir-mediated cell killing and 614 bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase 615 gene

Mode of cell death associated with 617 adenovirus-mediated suicide gene therapy in HNSCC tumor model

Transduction of human 619 pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a

herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to 621 ganciclovir

Fusion enzymes containing HSV-1 thymidine kinase 623 mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo

Enhancement of tumor ablation by a selected HSV-1

thymidine kinase mutant

CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Selective targeting of the oncogenic G12S 632 mutant allele by CRISPR/Cas9 induces efficient tumor regression

CRISPR/Cas9-mediated 634 cervical cancer treatment targeting human papillomavirus E6

Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment 636 using altered tropism of lentiviral vector

Off-target Effects in CRISPR/Cas9-mediated 639

Amplification-free 641 long-read sequencing reveals unforeseen CRISPR-Cas9 off-target activity

Latest Developed Strategies to Minimize the Off-Target 644

Effects in CRISPR-Cas-Mediated Genome Editing

Polo-like kinase 1 as target for cancer therapy

CRISPR-Cas9 genome

editing using targeted lipid nanoparticles for cancer therapy

Clinical approval of nanotechnology-based SARS-CoV-2 mRNA vaccines: impact 651 on translational nanomedicine

Lipid nanoparticle 653 technology for therapeutic gene regulation in the liver

On the role of helper lipids in lipid 655 nanoparticle formulations of siRNA

Selective killing of 657 hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic 658 pancreatic cancer

Transcriptional Targeting in Cancer Gene Therapy

VEGF regulates 662 haematopoietic stem cell survival by an internal autocrine loop mechanism

miRNA122a regulation of gene therapy vectors 664 targeting hepatocellular cancer stem cells

Evaluation of miR-122-regulated suicide gene 666 therapy for hepatocellular carcinoma in an orthotopic mouse model

Reduced expression of brain-enriched microRNAs in glioblastomas permits 669 targeted regulation of a cell death gene

Combinatorial control of suicide gene 671 expression by tissue-specific promoter and microRNA regulation for cancer therapy

Penetrating Lipid Nanoparticles for Delivery of Chemotherapeutics to Pancreatic Cancer Cell 675

In conclusion, we provide proof-of-concept work demonstrating the feasibility of targeting 448 HSV-tk and Cas9 therapeutic cargo to hypoxic tumor cells using LNPs. To the best of our 449 knowledge this is the first report demonstrating hypoxia specific expression and activity of the 450 CRISPR/Cas9 nuclease in tumor cells. This is also the first report proposing the delivery of a DNA 451 based hypoxia regulated gene therapy system using LNPs. The technologies presented here hold 452 tremendous potential in targeting some of the most aggressive and treatment resistant cells within 453 a solid tumor and should be explored further for enhanced cancer specificity and delivery. 454 455 Acknowledgements 456We thank the City of Hope Core Facilities for their support. In particular, we thank Dr. Zhuo Li and 457Dr. Ricardo Zerda at the COH Electron Microscopy and Atomic Force Microscopy core, as well 458 as Dr. Brian Armstrong at the COH Light Microscopy/Digital Imaging core for their expertise and 459 technical assistance. We thank the COH Analytical Cytometry core for their assistance. represented as mean ± S.D of triplicate treated samples, except (F) which represents mean ± S.D 514 of two independent samples; n.s. not significant; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 515